Diabetologia: Long-term effects of lipoprotein-associated phospholipase A2 on major coronary events by changing diabetes status

Lipoprotein-associated phospholipase A2 (LP-PLA2) and cardiac vascular health and prognosis associated, independent of low-density lipoprotein - cholesterol (LDL-c) and other traditional risk factors in coronary heart disease 19 years ago by the West of Scotland Prevention Study Established for the first time
.

Since then, several studies have repeated this finding, and LP-PLA2 has been identified as a viable drug target for the prevention of coronary events

Heart blood vessels cholesterol prevention of cardiovascular events, stroke

In the meta-analysis by Thompson et al.
concluded that observational studies failed to find evidence of the relationship between LP-PLA2 activity and ischemic stroke
.

The use of Darapladib myocardial infarction thrombolytic therapy to stabilize plaque 52 (Solid-TIMI 52) trial found that Darapladib does not reduce the risk of MCE in individuals who have experienced acute coronary events

Myocardial infarction diabetes

The discovery analysis was conducted in the diabetes genetics audit and study of the GoDARTS cohort in Scotland
.

GoDARTS is an observational cohort study in which 16,838 participants who agreed to participate in the study were recorded related medical and prescription history

A retrospective cohort study design was used in the two study populations
.

The subjects were classified according to the control status of type 2 diabetes: poorly controlled (glycated hemoglobin ≥<48 mmolmol or ≥6.

diagnosis

In GoDARTS, there is a significant interaction between the increase of Lp-PLA_2 activity (continuous and quartile) and diabetes control status (p<0.
0001)
.

These effects were also replicated in the stability of the placebo group (p<0.

Table 1 Baseline characteristics of the GoDARTS study cohort and stability test

 

 

Table 2 Risks in stratified risk groups based on Lp-PLA2 activity and diabetes status in GoDARTS (Figure 1)

 

 

Figure 1 GoDARTS study: a demonstration of all risk groups in GoDARTS
.

High Lp-PLA2 activity and low Lp-PLA2 activity (Q4 and Q1-3) and diabetes control status

 

The results indicate that the people most likely to benefit from inhibiting LP-PLA2 are those with high activity and type 2 diabetes
.

However, although not supported by experimental data, in people with diabetes, those with moderate levels of LP-PLA2 activity may also benefit from LP-PLA2 inhibition

 

Literature source: Siddiqui MK, Smith G, St Jean P, Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events, Diabetologia 2021 Sep 25;

Siddiqui MK, Smith G, St Jean P,Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events, Diabetologia 2021 Sep 25;

 

 

Leave a message here